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Dear Editor,
Kaposi’s sarcoma (KS) is a malignant vascular neoplasm
caused by Human Herpes virus type 8 (HHV-8) infection and
has been classiﬁed as an AIDS-deﬁning condition. Although
KS was observed in Africa before the AIDS epidemic, in the
African-endemic form, its incidence became substantially
higher with the increasing frequency of HIV infection. In
several African settings, it is now the most frequent cancer in
men and ranks second among women.1
In 2009, the prevalence of HIV was 11.5% (13.1% in
women and 9.2% in men) in the Mozambican population
aged 15–49 years.2 The GLOBOCAN project estimated an
overall number of 2,756 cases of KS for Mozambique in
2008, corresponding to crude incidence rates of 16.4/100,000
men and 8.5/100,000 women, and age-standardized rates
(world standard population) of 22.7/100,000 men and 9.6/
100,000 women.3 It was estimated to be the most frequent
among men and the second in women. These ﬁgures, how-
ever, were obtained as a weighted average of estimates for the
neighboring countries Malawi, Tanzania, and Zimbabwe.3
Here, we present local data on the observed incident cases
of KS. Population-based cancer incidence data are available
since 2005 from the Cancer Registry of Beira (ROB),4 a city
in the province of Sofala, with an estimated population of
approximately 450 thousand inhabitants in 2008.5 Data are
also available from the Pathology Department of the Maputo
Central Hospital (DP-HCM); this 1,500-bed hospital provides
the most specialized level of care in Mozambique and is the
national referral center. The DP-HCM receives virtually all
the specimens from Maputo City, with nearly 1.13 million
inhabitants.6
Table 1. All cases of cancer and cases of Kaposi sarcoma registered by the population-based Cancer Registry of the city of Beira and
diagnosed at the Pathology Department of the Maputo Central Hospital, among patients from Maputo City, in women and men (all ages)
Year of data collection
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Beira
All cancers
Women – – – – – 185 217 155 166 185 220
Men – – – – – 171 160 116 166 218 175
Kaposi sarcoma
Women – – – – – 82 60 40 35 56 57
Men – – – – – 106 88 61 112 129 99
Maputo
All cancers1
Women 319 304 329 357 668 572 649 690 747 777 877
Men 229 253 256 347 495 448 564 553 616 596 630
Kaposi sarcoma
Women 23 23 23 29 60 53 75 89 73 87 122
Men 47 35 47 74 93 89 108 132 101 131 174
1Excluding non-melanoma skin cancers.
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The ROB searches actively for the incident cases of cancer
in the central hospital, other public health care institutions
and private clinics in the city of Beira, and the deaths due to
oncological causes as depicted in the death certiﬁcate, which
contributes to the completeness of the registration. However,
the registry was set-up recently and is still improving the
procedures for identiﬁcation of cases in different institutions,
and its results also reﬂect the expectedly low intensity of di-
agnosis of several cancers, namely those requiring more spe-
cialized means. The records of the DP-HCM comprise data
from virtually all the patients with an anatomopathological
diagnosis (histology, cytology or autopsy) living in Maputo
city, although no information is available regarding liquid
tumors diagnosed at the Department of Clinical Pathology
and Hematology of the HCM, or patients with clinical diag-
nosis only. Although these sources may be expected to
underestimate the incidence of cancer in the populations of
the respective catchment areas, especially for Maputo City,
they provide lower bound estimates of the number of inci-
dence cases in these regions.
In the most recent years, KS was the most frequent cancer
among men and the second in women, both in Beira and in
Maputo. Table 1 shows a generally increasing trend in the
number of incident cases of cancer since 2000. This may be
explained changes in the risk and awareness of the popula-
tion for oncological diseases, especially those related with
AIDS, and in the resources available for diagnosis in these
settings. In Beira and Maputo, the age-standardized annual
incidence rates in the period 2007–2009 were 25.2/100,000 in
men and 14.2/100,000 in women, when using the age-struc-
ture of the national population estimates for 2008 as refer-
ence,7 and 34.2/100,000 in men and 16.2/100,000 in women,
when using the world standard population as reference.8,9
Although HIV infection is more prevalent in Sofala and
Maputo city than in the whole country (15–49 years: Maputo
city, 16.8%; Sofala, 15.5%2), the rates computed using data
from the ROB and the DP-HCM, expected to underestimate
the true incidence, are more than 1.5-fold higher than those
presented by GLOBOCAN.
In conclusion, our results on KS show that the burden of
AIDS-related cancers in Mozambique may be higher than
expected based on sources from neighboring countries. The
locally available population- and hospital-based data may be
used for a more accurate estimation of the burden of cancer
in this African setting.
Yours sincerely,
Carla Carrilho
Josefo Ferro
Cesaltina Lorenzoni
Thebora Sultane
Carla Silva-Matos
Nuno Lunet
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